Positions

Overview

  • Dr. Jeffrey R Curtis is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Curtis received a Medical Degree (MD) and a Master of Public Health (MPH) degree from Oregon Health & Sciences University in Portland, OR. He subsequently completed a residency in internal medicine at Oregon Health & Science University and a fellowship in rheumatology at UAB. He completed a graduate program in Clinical Informatics at Stanford University and received his Master of Science (MS) degree in epidemiology at the Harvard School of Public Health. He is board certified in both rheumatology and clinical informatics. Dr. Curtis currently holds the Marguerite Jones Harbert – Gene V. Ball Endowed Professorship in Rheumatology and Immunology at UAB. He is the Co-Director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit. PEER uses multiple large data sources to study comparative effectiveness questions across multiple chronic diseases. These data sources include national administrative data from Medicare and commercial health plans, electronic health record data, and large registries. In 2012, he was awarded the Henry Kunkel Young Investigator Award by the American College of Rheumatology (ACR) and was accepted into the American Society for Clinical Investigation (ASCI) in 2016. The evaluation of the efficacy, comparative effectiveness, and safety of the medications used to treat rheumatoid arthritis and spondyloarthritis are among Dr. Curtis’s research interests. He served on the Core Expert Panel for the ACR’s 2008, 2012, and 2015 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He was the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources. He is the Co-PI of the PCORI-funded Patient Powered Research Network “Arthritis-Power” registry, focused on RA, psoriasis, and psoriatic arthritis. He also leads the multi-center NIH-funded large pragmatic randomized controlled trial “VERVE” studying the safety and effectiveness of the live herpes zoster vaccine in patients receiving biologic agents. He is a member of the Center for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) Herpes Zoster workgroup. In 2015, he was appointed as a member to the FDA Arthritis Advisory Committee. Dr. Curtis also studies risk factors for and outcomes of osteoporosis. He was a member of the ACR’s task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures. Dr. Curtis is a member of the American College of Rheumatology (ACR), the International Society for Pharmacoepidemiology (ISPE), the American Medical Informatics Association (AMIA), and the American Society of Bone and Mineral Research (ASBMR). He has been on the editorial board for Arthritis & Rheumatism, Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care and Research (AC&R). He has authored more than 400 peer-reviewed manuscripts, review articles and book chapters.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3Arthritis and Rheumatology.  73:e60-e75. 2021
    2021 Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry 2021
    2021 Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.Annals of the Rheumatic Diseases.  80:1255-1265. 2021
    2021 The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial.Annals of Internal Medicine2021
    2021 A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational StudyRheumatology and Therapy.  8:1159-1176. 2021
    2021 A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's DiseaseGastroenterology.  161:837-852.e9. 2021
    2021 Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective AnalysisRheumatology and Therapy.  8:1383-1391. 2021
    2021 ReplyArthritis and Rheumatology.  73:1771-1772. 2021
    2021 ReplyArthritis and Rheumatology.  73:1769-1770. 2021
    2021 Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data from the IBM MarketScan® Administrative Claims Database with Tofacitinib Trial DataInflammatory Bowel Diseases.  27:1394-1408. 2021
    2021 Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness (RISE) Registry.Arthritis Care and Research2021
    2021 American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2.Arthritis and Rheumatology.  73:e30-e45. 2021
    2021 Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice–Based NetworkArthritis Care and Research.  73:1153-1161. 2021
    2021 Meaningful change thresholds for patient-reported outcomes measurement information system (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritisJournal of Rheumatology.  48:1239-1242. 2021
    2021 Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid ArthritisArthritis Care and Research.  73:1114-1124. 2021
    2021 Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.Annals of the Rheumatic Diseases2021
    2021 American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1Arthritis and Rheumatology.  73:1093-1107. 2021
    2021 Anca-Associated vasculitis management in the united states: Data from the rheumatology informatics system for effectiveness (rise) registryJournal of Rheumatology.  48:1060-1064. 2021
    2021 Economic Burden of Osteoporosis-Related Fractures in the US Medicare PopulationAnnals of Pharmacotherapy.  55:821-829. 2021
    2021 Evaluation of the Effect of Diabetes on Rheumatoid Arthritis-related Outcomes in an Electronic Health Record-based Rheumatology RegistryJournal of Rheumatology.  48:992-1001. 2021
    2021 Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death.Journal of Rheumatology2021
    2021 Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugsJournal of Rheumatology.  48:804-812. 2021
    2021 Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustmentClinical Rheumatology.  40:2419-2426. 2021
    2021 Treatment Strategies for Patients with Immune-Mediated Inflammatory Diseases 2021
    2021 Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained RemissionArthritis and Rheumatology.  73:759-768. 2021
    2021 Comparative effectiveness of biologics and targeted therapies for psoriatic arthritisRMD Open.  7. 2021
    2021 Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemicJournal of Rheumatology.  48:603-607. 2021
    2021 Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women’s Rheumatoid Arthritis Sequential Study RegistryArthritis Care and Research.  73:471-480. 2021
    2021 ArthritisPower Reflects Optimal Characteristics of Apps for Rheumatoid Arthritis 2021
    2021 Assessing rheumatologists’ attitudes and utilization of classification criteria for ankylosing spondylitis and axial spondyloarthritis: a global effortClinical Rheumatology.  40:949-954. 2021
    2021 Burden and trajectory of multimorbidity in rheumatoid arthritis: A matched cohort study from 2006 to 2015Annals of the Rheumatic Diseases.  80:286-292. 2021
    2021 Association of cardiovascular disease and traditional cardiovascular risk factors with the incidence of dementia among patients with rheumatoid arthritisSeminars in Arthritis and Rheumatism.  51:292-298. 2021
    2021 Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritisInternational Immunopharmacology.  91. 2021
    2021 Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different DiseasesArthritis Care and Research.  73:289-295. 2021
    2021 SARS CoV-2 infection among patients using immunomodulatory therapiesAnnals of the Rheumatic Diseases.  80:269-271. 2021
    2021 Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical VentilationAmerican Journal of Respiratory and Critical Care Medicine.  203:54-66. 2021
    2021 Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activityPLoS ONE.  16. 2021
    2021 Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial DataRheumatology and Therapy2021
    2021 Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE StudyRheumatology and Therapy2021
    2021 Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions 2021
    2020 Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database StudyScientific Reports.  10. 2020
    2020 Change in inappropriate critical care over timeJournal of Critical Care.  60:267-272. 2020
    2020 Circulating microbial small RNAs are altered in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  79:1557-1564. 2020
    2020 Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients 2020
    2020 Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patientsScientific Reports.  10. 2020
    2020 Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort StudyAnnals of Internal Medicine.  173:870-878. 2020
    2020 Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoidsPLoS ONE.  15. 2020
    2020 Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available 2020
    2020 Identifying Minimal and Meaningful Change in PROMIS® for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives.Arthritis Care and Research2020
    2020 The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adultsCleveland Clinic Journal of Medicine.  87:695-703. 2020
    2020 Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world dataAnnals of the Rheumatic Diseases.  79:1400-1413. 2020
    2020 What Does the Patient Global Health Assessment in Rheumatoid Arthritis Really Tell Us? Contribution of Specific Dimensions of Health-Related Quality of LifeArthritis Care and Research.  72:1571-1578. 2020
    2020 Long-term safety of tofacitinib up to 9.5 years: A comprehensive integrated analysis of the rheumatoid arthritis clinical development programmeRMD Open.  6. 2020
    2020 Performance of Administrative Algorithms to Identify Interstitial Lung Disease in Rheumatoid ArthritisArthritis Care and Research.  72:1392-1403. 2020
    2020 Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritisSeminars in Arthritis and Rheumatism.  50:988-995. 2020
    2020 Secular Trends in the Incidence of Hip Fracture Among Nursing Home ResidentsJournal of Bone and Mineral Research.  35:1668-1675. 2020
    2020 Enhancing Patient Understanding of Medication Risks and Benefits.Arthritis Care and Research2020
    2020 Physical activity measured using wearable activity tracking devices associated with gout flares 2020
    2020 Racial Disparities Exist in Outcomes After Major Fragility FracturesJournal of the American Geriatrics Society.  68:1803-1810. 2020
    2020 Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologicsJournal of Comparative Effectiveness Research.  9:767-779. 2020
    2020 Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United StatesPharmacoepidemiology and Drug Safety.  29:854-863. 2020
    2020 Trends of lymphoma incidence in US veterans with rheumatoid arthritis, 2002-2017RMD Open.  6. 2020
    2020 Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patientsOsteoarthritis and Cartilage.  28:917-923. 2020
    2020 Factors associated with the contemplative stage of readiness to initiate osteoporosis treatmentOsteoporosis International.  31:1283-1290. 2020
    2020 Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare DataPharmacoepidemiology and Drug Safety.  29:770-777. 2020
    2020 Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilarsPharmacoepidemiology and Drug Safety.  29:757-769. 2020
    2020 Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017Osteoporosis International.  31:1299-1304. 2020
    2020 Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid ArthritisArthritis Care and Research.  72:933-941. 2020
    2020 Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritisBMC Rheumatology.  4. 2020
    2020 Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States PhysiciansRheumatology and Therapy.  7:383-400. 2020
    2020 Harnessing health plan enrollee data to boost membership in patient-powered research networksBMC Health Services Research.  20. 2020
    2020 Duration of Bisphosphonate Drug Holidays and Associated Fracture RiskMedical Care.  58:419-426. 2020
    2020 Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgeryAnnals of the Rheumatic Diseases.  79:573. 2020
    2020 ReplyArthritis Care and Research.  72:736-738. 2020
    2020 Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications WorldwideJournal of Bone and Mineral Research.  35:996-997. 2020
    2020 Gout is associated with an increased risk for incident heart failure among older adults: The REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study 2020
    2020 An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational DataDrug Safety.  43:379-392. 2020
    2020 Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital TechnologyArthritis Care and Research.  72:553-560. 2020
    2020 Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-AnalysisArthritis Care and Research.  72:561-576. 2020
    2020 Incidence of serious infections and design of utilization and safety studies for biologic and biosimilar surveillance 2020
    2020 Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort studySeminars in Arthritis and Rheumatism.  50:228-236. 2020
    2020 Views of primary care physicians and rheumatologists regarding screening and treatment of hyperlipidemia among patients with rheumatoid arthritisBMC Rheumatology.  4. 2020
    2020 Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and RestartJournal of Bone and Mineral Research.  35:478-487. 2020
    2020 Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of RheumatologyArthritis Care and Research.  72:166-175. 2020
    2020 Barriers to treatment optimization and achievement of patients' goals: Perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry 2020
    2020 Incorporating patient generated health data into pharmacoepidemiological researchPharmacoepidemiology and Drug Safety2020
    2020 Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort StudyHypertension.  75:246-256. 2020
    2020 Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid ArthritisArthritis Care and Research2020
    2020 Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of GlucocorticoidsArthritis Care and Research2020
    2019 Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis 2019
    2019 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity MeasuresArthritis Care and Research.  71:1540-1555. 2019
    2019 International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working GroupArthritis Care and Research.  71:1556-1565. 2019
    2019 PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritisJournal of Patient-Reported Outcomes.  3. 2019
    2019 Screening of Hyperlipidemia Among Patients With Rheumatoid Arthritis in the United StatesArthritis Care and Research.  71:1593-1599. 2019
    2019 In responseAnnals of Internal Medicine.  171:680. 2019
    2019 Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With SulfasalazineArthritis Care and Research.  71:1326-1335. 2019
    2019 The Design and Validation of a New Algorithm to Identify Incident Fractures in Administrative Claims DataJournal of Bone and Mineral Research.  34:1798-1807. 2019
    2019 Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids - Clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole 2019
    2019 Assessing a novel way to measure three common rehabilitation outcome measures using a custom mobile phone applicationGait and Posture.  73:246-250. 2019
    2019 Digital tracking of rheumatoid arthritis longitudinally (digital) using biosensor and patient-reported outcome data: Protocol for a real-world studyJMIR Research Protocols.  8. 2019
    2019 Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world settingRMD Open.  5. 2019
    2019 Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USARheumatology and Therapy.  6:461-471. 2019
    2019 Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and GlucocorticoidsArthritis Care and Research.  71:1249-1254. 2019
    2019 Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative OutcomesArthritis Care and Research.  71:1224-1233. 2019
    2019 Anti-TNF and Physiologic Measures of Metabolic Disease in Rheumatoid Arthritis 2019
    2019 Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis PatientsArthritis Care and Research.  71:1004-1018. 2019
    2019 Assessing a novel way to measure step count while walking using a custom mobile phone applicationPLoS ONE.  13. 2019
    2019 Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasisEuropean Respiratory Journal.  54. 2019
    2019 The promise and perils of 'Big Data': focus on spondyloarthritisCurrent Opinion in Rheumatology.  31:355-361. 2019
    2019 Comparison of an interactive voice response system and smartphone application in the identification of gout flares 2019
    2019 Risk of biologics and glucocorticoids in patients with rheumatoid arthritis undergoing arthroplasty a cohort studyAnnals of Internal Medicine.  170:825-836. 2019
    2019 A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid ArthritisPharmacoEconomics.  37:829-843. 2019
    2019 Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritisRheumatology.  58:874-883. 2019
    2019 Digital Interventions to Build a Patient Registry for Rheumatology ResearchRheumatic Disease Clinics of North America.  45:173-186. 2019
    2019 Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: A pooled analysis of 11 317 patients across clinical trialsRMD Open.  5. 2019
    2019 Opioid use in rheumatoid arthritis: trends, efficacy, safety, and best practicesCurrent Opinion in Rheumatology.  31:264-270. 2019
    2019 The Interface Between Digital Health and RheumatologyRheumatic Disease Clinics of North America.  45:xv-xvi. 2019
    2019 Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data LinkagesRheumatic Disease Clinics of North America.  45:275-289. 2019
    2019 Toward relevant and credible cost-effectiveness analyses for value assessment in the decentralized U.S. health care system 2019
    2019 Data linkages between patient-powered research networks and health plans: A foundation for collaborative researchJournal of the American Medical Informatics Association.  26:594-602. 2019
    2019 Improved Quality of Life with Anti-TNF Therapy Compared with Continued Corticosteroid Utilization in Crohn's DiseaseInflammatory Bowel Diseases.  25:925-936. 2019
    2019 Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study 2019
    2019 Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United StatesCurrent Medical Research and Opinion.  35:603-609. 2019
    2019 Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United StatesCurrent Medical Research and Opinion.  35:611-617. 2019
    2019 Contraception methods used by women with rheumatoid arthritis and psoriatic arthritisClinical Rheumatology.  38:1207-1212. 2019
    2019 Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United StatesJournal of Rheumatology.  46:237-244. 2019
    2019 Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scoresClinical Rheumatology.  38:437-445. 2019
    2019 A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator TrialsArthritis Care and Research.  71:319-322. 2019
    2019 Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and OkadaAnnals of the Rheumatic Diseases.  78. 2019
    2019 Risk of subsequent fracture after prior fracture among older womenOsteoporosis International.  30:79-92. 2019
    2019 Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritisAnnals of the Rheumatic Diseases2019
    2019 Direct-acting antivirals for hepatitis C: Predictors of early discontinuation in the real world 2019
    2019 Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritisPLoS ONE.  14. 2019
    2019 Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative StudyArthritis Care and Research.  71:80-87. 2019
    2019 Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studiesCurrent Medical Research and Opinion.  35:1483-1493. 2019
    2019 Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitorJournal of Rheumatology.  46:475-482. 2019
    2019 The prevalence and types of discordance between physician perception and objective data from standardized measures of rheumatoid arthritis disease activity in real-world clinical practice in the USBMC Rheumatology.  3. 2019
    2019 Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?BMC Rheumatology.  3. 2019
    2018 Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014Chest.  154:1311-1320. 2018
    2018 Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) studyArchives of Osteoporosis.  13. 2018
    2018 Importance of Recent Fracture as Predictor of Imminent Fracture RiskCurrent Osteoporosis Reports.  16:738-745. 2018
    2018 Correction to: Hip fracture trends in the United States, 2002 to 2015 (Osteoporosis International, (2018), 29, 3, (717-722), 10.1007/s00198-017-4345-0)Osteoporosis International.  29:2583. 2018
    2018 Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?Arthritis Care and Research.  70:1694-1699. 2018
    2018 Evaluation of a Methodologic Approach to Define an Inception Cohort of Rheumatoid Arthritis Patients Using Administrative DataArthritis Care and Research.  70:1541-1545. 2018
    2018 Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected ConditionsJournal of Bone and Mineral Research.  33:1881-1888. 2018
    2018 Patient Governance in a Patient-Powered Research Network for Adult Rheumatologic ConditionsMedical Care.  56:S16-S21. 2018
    2018 Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort StudyArthritis and Rheumatology.  70:1565-1571. 2018
    2018 Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritisQuality of Life Research.  27:2443-2451. 2018
    2018 Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional studyClinical Rheumatology.  37:2331-2340. 2018
    2018 Opioids vs nonopioids for chronic back, hip, or knee pain 2018
    2018 An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical ApproachesThe Permanente Journal.  22. 2018
    2018 Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitorsAnnals of the Rheumatic Diseases.  77:1012-1016. 2018
    2018 Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for CliniciansDrug Safety.  41:545-553. 2018
    2018 Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept 2018
    2018 Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid ArthritisRheumatology and Therapy.  5:283-291. 2018
    2018 Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients 2018
    2018 Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical TrialJournal of Bone and Mineral Research.  33:763-772. 2018
    2018 Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid ArthritisArthritis Care and Research.  70:679-684. 2018
    2018 Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysisPLoS ONE.  13. 2018
    2018 Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoidsAnnals of the Rheumatic Diseases.  77:644-649. 2018
    2018 ReplyArthritis and Rheumatology.  70:795-796. 2018
    2018 Defining and characterizing sustained remission in patients with rheumatoid arthritisClinical Rheumatology.  37:885-893. 2018
    2018 Use of Scribes for Documentation Assistance in Rheumatology and Endocrinology Clinics: Impact on Clinic Workflow and Patient and Physician Satisfaction 2018
    2018 Effectiveness and safety of tofacitinib in rheumatoid arthritis: A cohort study 2018
    2018 Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based studyAnnals of the Rheumatic Diseases.  77:386-392. 2018
    2018 Hip fracture trends in the United States, 2002 to 2015Osteoporosis International.  29:717-722. 2018
    2018 Advancing the Science and Practice of Medication AdherenceJournal of General Internal Medicine.  33:216-222. 2018
    2018 Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritisSeminars in Arthritis and Rheumatism.  47:472-477. 2018
    2018 Just the FRAX: Management of Glucocorticoid-Induced OsteoporosisGastroenterology.  154:748-750. 2018
    2018 ReplyArthritis and Rheumatology.  70:320. 2018
    2018 Development of algorithms for identifying fatal cardiovascular disease in Medicare claimsPharmacoepidemiology and Drug Safety2018
    2018 Incidence and prevalence of axial spondyloarthritis: Methodologic challenges and gaps in the literatureClinical and Experimental Rheumatology.  36:263-274. 2018
    2018 Lipid management among individuals with inflammatory arthritis in the national REasons for geographic and racial differences in stroke (REGARDS) cohortJournal of International Medical Research.  46:62-69. 2018
    2018 Routine use of quantitative disease activity measurements among us rheumatologists: Implications for treat-to-target management strategies in rheumatoid arthritisJournal of Rheumatology.  45:40-44. 2018
    2017 Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment 2017
    2017 Studies with herpes zoster vaccines in immune compromised patientsExpert Review of Vaccines.  16:1217-1230. 2017
    2017 Critical outcomes in longitudinal observational studies and registries in patients with rheumatoid arthritis: An OMERACT special interest group reportJournal of Rheumatology.  44:1894-1898. 2017
    2017 Herpes Zoster as a Risk Factor for Incident Giant Cell ArteritisArthritis and Rheumatology.  69:2351-2358. 2017
    2017 Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee ArthroplastyArthritis Care and Research.  69:1845-1854. 2017
    2017 Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research RegistryChest.  152:1120-1127. 2017
    2017 Serious Infections in Childhood-Onset Systemic Lupus Erythematosus: Using Administrative Claims Data to Investigate Disease OutcomesArthritis Care and Research.  69:1617-1619. 2017
    2017 Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study 2017
    2017 Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant TherapyArthritis and Rheumatology.  69:1960-1968. 2017
    2017 Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid ArthritisArthritis Care and Research.  69:1526-1534. 2017
    2017 The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trialOsteoporosis International.  28:3061-3066. 2017
    2017 The effects of a patient activation intervention on smoking and excessive drinking cessations: results from the PAADRN randomized controlled trialOsteoporosis International.  28:3055-3060. 2017
    2017 A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: Post-hoc results from the certolizumab pegol phase 4 PREDICT trial 2017
    2017 Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United StatesArthritis and Rheumatology.  69:1733-1740. 2017
    2017 Stakeholders' views on data sharing in multicenter studiesJournal of Comparative Effectiveness Research.  6:537-547. 2017
    2017 Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study (Osteoporosis International, (2017), 28, 8, (2495-2503), 10.1007/s00198-017-4073-5)Osteoporosis International.  28:2505. 2017
    2017 Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor–Alpha Experienced Rheumatoid Arthritis 2017
    2017 Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trialsAnnals of the Rheumatic Diseases.  76:1253-1262. 2017
    2017 Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseasesJournal of Rheumatology.  44:1083-1087. 2017
    2017 Knee Pain and Structural Damage as Risk Factors for Incident Widespread Pain: Data From the Multicenter Osteoarthritis StudyArthritis Care and Research.  69:826-832. 2017
    2017 Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot studyOsteoporosis International.  1-9. 2017
    2017 Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: A retrospective claims analysis 2017
    2017 Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis 2017
    2017 Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritisClinical and Experimental Rheumatology.  35:0390-0400. 2017
    2017 Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.Clinical and Experimental Rheumatology.  35:390-400. 2017
    2017 Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis c virus infectionJournal of Rheumatology.  44:565-570. 2017
    2017 Improving medical record retrieval for validation studies in Medicare dataPharmacoepidemiology and Drug Safety.  26:393-401. 2017
    2017 Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et alArthritis and Rheumatology.  69:863-865. 2017
    2017 Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetesBMC Cardiovascular Disorders.  17. 2017
    2017 Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising 2017
    2017 Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid ArthritisArthritis Care and Research.  69:313-322. 2017
    2017 The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insightsPharmacoepidemiology and Drug Safety.  26:310-319. 2017
    2017 Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinibClinical Rheumatology.  36:683-688. 2017
    2017 Herpes Zoster and the Risk of Stroke in Patients With Autoimmune DiseasesArthritis and Rheumatology.  69:439-446. 2017
    2017 Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programmeClinical and Experimental Rheumatology.  35:614-622. 2017
    2017 Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults secondary analysis of a randomized clinical trialJAMA Internal Medicine.  177:67-76. 2017
    2017 Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled TrialArthritis and Rheumatology.  69:46-57. 2017
    2016 A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention materialContemporary Clinical Trials Communications.  4:14-24. 2016
    2016 Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study 2016
    2016 Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medicationClinicoEconomics and Outcomes Research.  8:707-715. 2016
    2016 Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry 2016
    2016 Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid ArthritisArthritis Care and Research.  68:1751-1757. 2016
    2016 Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009The Permanente Journal.  20:4-12. 2016
    2016 Usability and workflow evaluation of “RhEumAtic disease activity” (READY): A mobile application for rheumatology patients and providersApplied Clinical Informatics.  7:1007-1024. 2016
    2016 Adherence and persistence with methotrexate in rheumatoid arthritis: A systematic reviewJournal of Rheumatology.  43:1997-2009. 2016
    2016 Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic TreatmentsArthritis and Rheumatology.  68:2612-2617. 2016
    2016 Comparaison du certolizumab pegol versus adalimumab : résultats d'efficacité et de tolérance à 2 ans d'une étude comparative directe de supériorité, en aveugle pour les investigateursRevue du Rhumatisme.  83:A125-A126. 2016
    2016 Erratum: Corrigendum to “Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases” (Clinical Therapeutics (2016) 38(6) (1451–1463)(S0149291816301849)(10.1016/j.clinthera.2016.03.038)) 2016
    2016 Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritisOsteoporosis International.  27:3239-3249. 2016
    2016 Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans 2016
    2016 Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort StudyArthritis and Rheumatology.  68:2403-2411. 2016
    2016 Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  75:1813-1818. 2016
    2016 Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritisAnnals of the Rheumatic Diseases.  75:1757-1762. 2016
    2016 Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  75:1843-1847. 2016
    2016 Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritisBMC Musculoskeletal Disorders.  17. 2016
    2016 The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis 2016
    2016 Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients 2016
    2016 Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care SettingThe Permanente Journal.  20:4-10. 2016
    2016 Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein–Enriched Serum in Rheumatoid ArthritisArthritis and Rheumatology.  68:2099-2105. 2016
    2016 Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) StudyContemporary Clinical Trials.  50:106-115. 2016
    2016 Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for VaccinationArthritis and Rheumatology.  68:2328-2337. 2016
    2016 Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: A randomized controlled trialBMC Musculoskeletal Disorders.  17. 2016
    2016 A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis studyContemporary Clinical Trials Communications.  3:32-38. 2016
    2016 What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective StudyJournal of Bone and Mineral Research.  31:1500-1503. 2016
    2016 Survival rates of cancer patients with and without rheumatic disease: A retrospective cohort analysisBMC Cancer.  16. 2016
    2016 Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication usePharmacoepidemiology and Drug Safety.  25:827-835. 2016
    2016 Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back PainArthritis and Rheumatology.  68:1669-1676. 2016
    2016 Agreement between rheumatologist and patient-reported adherence to methotrexate in a US rheumatoid arthritis registryJournal of Rheumatology.  43:1027-1029. 2016
    2016 Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona RegistryRheumatology and Therapy.  3:103-115. 2016
    2016 Initial Experience with Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination with Conventional Synthetic DMARDs in 2 US Health Care Claims Databases 2016
    2016 Reenergizing Research While Improving Patient Care 2016
    2016 Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abataceptBMC Musculoskeletal Disorders.  17. 2016
    2016 Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical development programmeAnnals of the Rheumatic Diseases.  75:831-841. 2016
    2016 Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations 2016
    2016 Association of Triple Therapy with Improvement in Cholesterol Profiles over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis TrialArthritis and Rheumatology.  68:577-586. 2016
    2016 Comparative effectiveness of etanercept and adalimumab in patient reported outcomes and injection-related tolerabilityPLoS ONE.  11. 2016
    2016 Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: Data from the National Veterans Health AdministrationAnnals of the Rheumatic Diseases.  75:341-347. 2016
    2016 Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancerJAMA Dermatology.  152:164-172. 2016
    2016 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis and Rheumatology.  68:1-26. 2016
    2016 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis and Rheumatology.  68:1-26. 2016
    2016 Association of reduced eGFR and albuminuria with serious fall injuries among older adultsClinical Journal of the American Society of Nephrology.  11:1236-1243. 2016
    2016 Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in MedicareArthritis and Rheumatology.  68:56-66. 2016
    2016 Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents.J Psoriasis Psoriatic Arthritis.  1:128-137. 2016
    2016 Risk of Subsequent Infection among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic DrugsArthritis and Rheumatology.  68:67-76. 2016
    2015 A randomized trial comparing disease activity measures for the assessment and prediction of response in rheumatoid arthritis patients initiating certolizumab pegolArthritis and Rheumatology.  67:3104-3112. 2015
    2015 Herpes Zoster Reactivation in Patients with Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic DrugsArthritis Care and Research.  67:1671-1678. 2015
    2015 The Risk for Cardiovascular Events Associated with Hyperlipdemia among Patients with and Without Rheumatoid Arthritis.Journal of Arthritis.  4. 2015
    2015 The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare populationBritish Journal of Clinical Pharmacology.  80:1447-1457. 2015
    2015 Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor aα agents, a retrospective cohort study 2015
    2015 Bone mineral density as a predictor of subsequent wrist fractures: Findings from the women's health initiative studyJournal of Clinical Endocrinology and Metabolism.  100:4315-4324. 2015
    2015 Effectiveness and costs of biologics in veterans with rheumatoid arthritisThe American journal of pharmacy benefits.  7:280-289. 2015
    2015 Methotrexate Adherence Questionnaire: a New Tool to Assess Adherence in Patients Treated with Methotrexate.Value in Health.  18:A714-A715. 2015
    2015 Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative StudyJournal of Bone and Mineral Research.  30:2086-2095. 2015
    2015 Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veteransBONE.  78:174-185. 2015
    2015 Heterogeneous disease trajectories explain variable radiographic, function and quality of life outcomes in the Canadian Early Arthritis Cohort (CATCH)PLoS ONE.  10. 2015
    2015 The validity of claims-based algorithms to identify serious hypersensitivity reactions and osteonecrosis of the jawPLoS ONE.  10. 2015
    2015 Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in crohn's diseaseClinical Gastroenterology and Hepatology.  13:1293-1301.e5. 2015
    2015 Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: Persistent benefits. Data from the Corrona registryAnnals of the Rheumatic Diseases.  74:1150-1155. 2015
    2015 Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapyAnnals of the Rheumatic Diseases.  74:1065-1071. 2015
    2015 Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: A retrospective cohort study 2015
    2015 DXA utilization between 2006 and 2012 in commercially insured younger postmenopausal womenJournal of Clinical Densitometry.  18:145-149. 2015
    2015 Proceedings from the American College of Rheumatology Reproductive Health Summit: The management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseasesArthritis Care and Research.  67:313-325. 2015
    2015 An evaluation of clinical risk factors for estimating fracture risk in postmenopausal osteoporosis using an electronic medical record databaseOsteoporosis International.  26:581-587. 2015
    2015 The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factorAnnals of the Rheumatic Diseases.  74:430-436. 2015
    2015 An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid usersJournal of Rheumatology.  42:1478-1483. 2015
    2015 Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: A substudyArthritis Care and Research.  67:929-939. 2015
    2015 Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured populationJournal of Managed Care Pharmacy.  21:318-328. 2015
    2015 Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: A consortium of rheumatology researchers of North America registry studyArthritis and Rheumatology.  67:1995-2003. 2015
    2015 Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis PatientsArthritis Care and Research.  67:1345-1353. 2015
    2015 Disease activity in rheumatoid arthritis and the risk of cardiovascular eventsArthritis and Rheumatology.  67:1449-1455. 2015
    2015 Fractures and mortality in relation to different osteoporosis treatmentsClinical and Experimental Rheumatology.  33:302-309. 2015
    2015 Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patientsArthritis Care and Research.  67:624-632. 2015
    2015 International management of bone health in glucocorticoid-exposed individuals in the observational GLOW studyOsteoporosis International.  26:419-420. 2015
    2015 Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare systemJournal of Rheumatology.  42:504-512. 2015
    2015 Mortality associated with medical therapy versus elective colectomy in ulcerative colitis a cohort studyAnnals of Internal Medicine.  163:262-270. 2015
    2015 ReplyArthritis Care and Research.  67:1041-1042. 2015
    2015 Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumabArthritis and Rheumatology.  67:1456-1464. 2015
    2015 Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapyArthritis Care and Research.  67:731-736. 2015
    2015 Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sourcesSeminars in Arthritis and Rheumatism.  44:381-388. 2015
    2014 The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritisPostgraduate Medical Journal.  90:722-729. 2014
    2014 Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: Results of the SAfety assessment of biologic ThERapy (SABER) studyAnnals of the Rheumatic Diseases.  73:1942-1948. 2014
    2014 The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spineJournal of Bone and Mineral Research.  29:2520-2526. 2014
    2014 Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United StatesArthritis Care and Research.  66:1604-1611. 2014
    2014 Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the veterans health administration 2014
    2014 Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasisJournal of the European Academy of Dermatology and Venereology.  28:1380-1387. 2014
    2014 Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritisJournal of Rheumatology.  41:1935-1943. 2014
    2014 Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitorsJournal of Rheumatology.  41:2078-2084. 2014
    2014 Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs 2014
    2014 Estimating effectiveness and cost of biologics for rheumatoid arthritis: Application of a validated algorithm to commercial insurance claims 2014
    2014 Claims-based algorithms for identifying Medicare beneficiaries at high estimated risk for coronary heart disease events: A cross-sectional studyBMC Health Services Research.  14. 2014
    2014 Design characteristics of the CORRONA CERTAIN study: A comparative effectiveness study of biologic agents for rheumatoid arthritis patientsBMC Musculoskeletal Disorders.  15. 2014
    2014 Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiariesBMC Musculoskeletal Disorders.  15. 2014
    2014 Death, debility, and destitution following hip fracture 2014
    2014 Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugsSeminars in Arthritis and Rheumatism.  43:489-497. 2014
    2014 Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatmentJournal of Rheumatology.  41:216-226. 2014
    2014 Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: Results from the treatment of early aggressive rheumatoid arthritis trial 2014
    2014 High plasma levels of vitamin C and E are associated with incident radiographic knee osteoarthritisOsteoarthritis and Cartilage.  22:190-196. 2014
    2014 Use of health plan combined with registry data to predict clinical trial recruitmentClinical Trials.  11:96-101. 2014
    2014 A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumabAnnals of the Rheumatic Diseases.  73:1429-1430. 2014
    2014 Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral researchJournal of Bone and Mineral Research.  29:1-23. 2014
    2014 Comparative effectiveness of infliximab and adalimumab for crohn's diseaseClinical Gastroenterology and Hepatology.  12:811-817.e3. 2014
    2014 Considerations in using registry and health plan data for studying pregnancy in rheumatic diseasesCurrent Opinion in Rheumatology.  26:315-320. 2014
    2014 Effect of self-referral on bone mineral density testing and osteoporosis treatmentMedical Care.  52:743-750. 2014
    2014 Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritisAnnals of the Rheumatic Diseases.  73:785-786. 2014
    2014 Linkage of a de-identified united states rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness researchArthritis Care and Research.  66:1790-1798. 2014
    2014 ReplyArthritis Care and Research.  66:1271-1272. 2014
    2014 Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritisArthritis Care and Research.  66:990-997. 2014
    2014 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-Label, longterm extension studiesJournal of Rheumatology.  41:837-852. 2014
    2014 The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  73:1301-1308. 2014
    2014 Trends in the utilization and outcomes of medicare patients hospitalized for hip fracture, 2000-2008Journal of Aging and Health.  26:360-379. 2014
    2014 Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis 2014
    2014 Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone massOsteoporosis International.  25:317-324. 2014
    2014 Vaccinations for rheumatoid arthritisCurrent Rheumatology Reports.  16. 2014
    2014 Validity of claims-based stroke algorithms in contemporary medicare data: Reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claimsCirculation: Cardiovascular Quality and Outcomes.  7:611-619. 2014
    2013 Commentary: Measuring quality of care in osteoporosisCurrent Osteoporosis Reports.  11:338-340. 2013
    2013 Commentary: The five ws of a fracture liaison service: Why, who, what, where, and how? in osteoporosis, we reap what we sowCurrent Osteoporosis Reports.  11:365-368. 2013
    2013 Epidemiologic research of invasive fungal infections using large healthcare databasesCurrent Fungal Infection Reports.  7:320-325. 2013
    2013 Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonistAnnals of the Rheumatic Diseases.  72:1813-1818. 2013
    2013 Identifying newly approved medications in Medicare claims data: A case study using tocilizumabPharmacoepidemiology and Drug Safety.  22:1214-1221. 2013
    2013 Tumor necrosis factor, tuberculosis, testing, and treatment: Teeing up the questionsArthritis Care and Research.  65:1719-1721. 2013
    2013 Tumor necrosis factor, tuberculosis, testing, and treatment: teeing up the questions.Arthritis Care and Research.  65:1719-1721. 2013
    2013 Using registries to identify adverse events in rheumatic diseasesPediatrics.  132. 2013
    2013 Challenges in defining quality of care for glucocorticoid-induced osteoporosis: Defending good against perfectJournal of Rheumatology.  40:1640-1642. 2013
    2013 Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosisPharmacoepidemiology and Drug Safety.  22:1107-1114. 2013
    2013 Multimodal intervention to improve osteoporosis care in home health settings: Results from a cluster randomized trialOsteoporosis International.  24:2555-2560. 2013
    2013 Patient perspectives on achieving treat-to-target goals: A critical examination of patient-reported outcomesArthritis Care and Research.  65:1707-1712. 2013
    2013 Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patientsSeminars in Arthritis and Rheumatism.  43:137-143. 2013
    2013 ReplyAmerican Journal of Ophthalmology.  156:408. 2013
    2013 Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: Results from a two-year randomized, double-blind trialArthritis and Rheumatism.  65:1985-1994. 2013
    2013 Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009Pharmacoepidemiology and Drug Safety.  22:842-849. 2013
    2013 Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009Journal of Rheumatology.  40:1218-1225. 2013
    2013 Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseasesArthritis Care and Research.  65:1085-1094. 2013
    2013 Osteoporosis medication adherence: Physician perceptions vs. patients' utilizationBONE.  55:1-6. 2013
    2013 Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: A one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study)Clinical and Experimental Rheumatology.  31:358-364. 2013
    2013 Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: Results from the treatment of early rheumatoid arthritis trialArthritis and Rheumatism.  65:1430-1438. 2013
    2013 Brief report: Incidence of selected opportunistic infections among children with juvenile idiopathic arthritisArthritis and Rheumatism.  65:1384-1389. 2013
    2013 Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: Results from the TEAR trialJournal of Rheumatology.  40:572-578. 2013
    2013 New methods for determining comparative effectiveness in rheumatoid arthritisCurrent Opinion in Rheumatology.  25:325-333. 2013
    2013 Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritisCurrent Opinion in Rheumatology.  25:384-390. 2013
    2013 Development of a Multi-Biomarker Disease Activity Test for Rheumatoid ArthritisPLoS ONE.  8. 2013
    2013 A close examination of healthcare expenditures related to fracturesJournal of Bone and Mineral Research.  28:816-820. 2013
    2013 Association between anti-TNF-α therapy and interstitial lung diseasePharmacoepidemiology and Drug Safety.  22:394-402. 2013
    2013 Performance of FRAX in a cohort of community-dwelling, ambulatory older men: The Osteoporotic Fractures in Men (MrOS) studyOsteoporosis International.  24:1185-1193. 2013
    2013 Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data 2013
    2013 Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster 2013
    2013 Magnitude and consequences of misclassification of incident hip fractures in large cohort studies: The Study of Osteoporotic Fractures and Medicare claims dataOsteoporosis International.  24:801-810. 2013
    2013 Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritisJournal of Rheumatology.  40:127-136. 2013
    2013 Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting SystemArthritis Care and Research.  65:235-243. 2013
    2013 Generic alendronate use among medicare beneficiaries: Are part d data complete?Pharmacoepidemiology and Drug Safety.  22:55-63. 2013
    2013 Initiation of anti-TNF therapy and the risk of optic neuritis: From the safety assessment of biologic ThERapy (SABER) studyAmerican Journal of Ophthalmology.  155:183-189.e1. 2013
    2013 Low hemoglobin levels and recurrent falls in U.S. Men and Women: Prospective findings from the REasons for Geographic and racial differences in stroke (REGARDS) cohortAmerican Journal of the Medical Sciences.  345:446-454. 2013
    2013 Mycobacterial diseases and antitumour necrosis factor therapy in USAAnnals of the Rheumatic Diseases.  72:37-42. 2013
    2013 Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis 2013
    2013 The PAADRN Study: A design for a randomized controlled practical clinical trial to improve bone healthContemporary Clinical Trials.  34:90-100. 2013
    2013 Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare programArthritis Care and Research.  65:1743-1751. 2013
    2013 Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseasesArthritis and Rheumatism.  65:48-58. 2013
    2013 Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: Feasibility, satisfaction, and sample sizePatient Preference and Adherence.  7:517-523. 2013
    2012 A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal womenJournal of Bone and Mineral Research.  27:2603-2610. 2012
    2012 Association between anti-TNF-α therapy and all-cause mortalityPharmacoepidemiology and Drug Safety.  21:1311-1320. 2012
    2012 Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational dataArthritis Care and Research.  64:1855-1863. 2012
    2012 Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritisArthritis Care and Research.  64:1819-1828. 2012
    2012 Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritisArthritis Care and Research.  64:1804-1810. 2012
    2012 Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityArthritis Care and Research.  64:1794-1803. 2012
    2012 Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United StatesContemporary Clinical Trials.  33:1211-1216. 2012
    2012 Recent trends in hip fracture rates by race/ethnicity among older US adultsJournal of Bone and Mineral Research.  27:2325-2332. 2012
    2012 Postherpetic neuralgia after herpes zoster vaccination - Reply 2012
    2012 Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patientsArthritis Care and Research.  64:1480-1489. 2012
    2012 A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trialArthritis and Rheumatism.  64:2824-2835. 2012
    2012 Defining physiologically "normal" vitamin D in African AmericansOsteoporosis International.  23:2283-2291. 2012
    2012 Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapyArthritis Care and Research.  64:1282-1291. 2012
    2012 Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatmentArthritis and Rheumatism.  64:2773-2780. 2012
    2012 Association between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection among Older Patients with Selected Immune-Mediated Diseases 2012
    2012 Management of osteoporosis among the elderly with other chronic medical conditionsDrugs and Aging.  29:549-564. 2012
    2012 Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare populationArthritis Care and Research.  64:1054-1060. 2012
    2012 Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: A post-hoc analysis of the RAPID 1 trialJournal of Rheumatology.  39:1326-1333. 2012
    2012 Association of intact parathyroid hormone levels with subsequent hip BMD loss: The Osteoporotic Fractures in Men (MrOS) studyJournal of Clinical Endocrinology and Metabolism.  97:1937-1944. 2012
    2012 Malignancy validation in a United States registry of rheumatoid arthritis patientsBMC Musculoskeletal Disorders.  13. 2012
    2012 Comparative safety of infliximab and etanercept on the risk of serious infections: Does the association vary by patient characteristics?Pharmacoepidemiology and Drug Safety.  21:524-534. 2012
    2012 Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapyApplied Health Economics and Health Policy.  10:163-173. 2012
    2012 Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changesJournal of Bone and Mineral Research.  27:858-864. 2012
    2012 Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseasesArthritis Care and Research.  64:612-615. 2012
    2012 Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendationsArthritis and Rheumatism.  64:630-638. 2012
    2012 Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: The ROSE studyAnnals of the Rheumatic Diseases.  71:198-205. 2012
    2012 In responseEmerging Infectious Diseases.  18:361. 2012
    2012 Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: Exploratory analyses from the TEMPO trialAnnals of the Rheumatic Diseases.  71:206-212. 2012
    2012 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care and Research.  64:625-639. 2012
    2012 Evaluating comorbidity scores based on health service expendituresMedicare & medicaid research review.  2. 2012
    2012 Improving osteoporosis care in high-risk home health patients through a high-intensity interventionContemporary Clinical Trials.  33:206-212. 2012
    2012 Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health planBONE.  50:870-875. 2012
    2012 Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year.Arthritis Care and Research.  64:658-667. 2012
    2012 Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.Arthritis and Rheumatism.  64:1263-1271. 2012
    2012 ReplyArthritis Care and Research.  64:157-158. 2012
    2012 Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor 2012
    2012 Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Atypical Femoral Fractures Using Administrative Claims DataJournal of Clinical Densitometry.  15:92-102. 2012
    2011 Initiation of tumor necrosis factor-αantagonists and the risk of hospitalization for infection in patients with autoimmune diseases 2011
    2011 Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practiceArthritis Care and Research.  63:1680-1690. 2011
    2011 Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: A retrospective pooled analysisRheumatology.  50:2223-2232. 2011
    2011 Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohortArthritis Care and Research.  63:1672-1679. 2011
    2011 Study design for a comprehensive assessment of biologic safety using multiple healthcare data systemsPharmacoepidemiology and Drug Safety.  20:1199-1209. 2011
    2011 Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patientsPharmacoepidemiology and Drug Safety.  20:1150-1158. 2011
    2011 The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: A longitudinal observational study 2011
    2011 Changes in cotherapies after initiation of disease - Modifying antirheumatic drug therapy in patients with rheumatoid arthritisArthritis Care and Research.  63:1415-1424. 2011
    2011 Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis 2011
    2011 Geographic distribution of endemic fungal infections among older persons, United StatesEmerging Infectious Diseases.  17:1664-1669. 2011
    2011 Developing a construct to evaluate flares in rheumatoid arthritis: A conceptual report of the OMERACT RA Flare Definition Working GroupJournal of Rheumatology.  38:1745-1750. 2011
    2011 Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: An analysis of individual patient-level dataArthritis and Rheumatism.  63:2203-2208. 2011
    2011 Erratum: Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research (Journal of Bone and Mineral Research (2010) 25 (2267-2294))Journal of Bone and Mineral Research.  26:1987. 2011
    2011 Improving osteoporosis care through multimodal interventions: Insights from the University of Alabama at Birmingham Center for Education and Research on TherapeuticsOsteoporosis International.  22. 2011
    2011 Long-term safety concerns of antiresorptive therapyRheumatic Disease Clinics of North America.  37:387-400. 2011
    2011 The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsAnnals of the Rheumatic Diseases.  70:1401-1406. 2011
    2011 Consistency of knee pain and risk of knee replacement: The multicenter osteoarthritis studyJournal of Rheumatology.  38:1390-1395. 2011
    2011 Corrigendum to "Cost burden of second fracture in the US Health System" [Bone 48 (2011) 828-836]BONE.  48:1429. 2011
    2011 Medical costs of osteoporosis in the elderly Medicare populationOsteoporosis International.  22:1835-1844. 2011
    2011 Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of a randomized controlled trialJournal of Rheumatology.  38:990-996. 2011
    2011 Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care 2011
    2011 High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  70:785-791. 2011
    2011 Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trialsMedical Care.  49:427-435. 2011
    2011 Response to Letter to Editor on validation study identifying bacterial infections in rheumatoid arthritis patientsJournal of Clinical Epidemiology.  64:573. 2011
    2011 Cost burden of second fracture in the US Health SystemBONE.  48:828-836. 2011
    2011 Erratum: Clinical and demographic factors associated with fractures among older Americans (Osteoporosis International DOI: 10.1007/s00198-010-1300-8)Osteoporosis International.  22:1275-1276. 2011
    2011 The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trialJournal of Bone and Mineral Research.  26:683-688. 2011
    2011 Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  70:576-582. 2011
    2011 TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritisMedicine.  90:139-145. 2011
    2011 The incidence of gastrointestinal perforations among rheumatoid arthritis patientsArthritis and Rheumatism.  63:346-351. 2011
    2011 Clinical and demographic factors associated with fractures among older AmericansOsteoporosis International.  22:1263-1274. 2011
    2011 Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologicsCurrent Medical Research and Opinion.  27:71-78. 2011
    2011 Official Positions for FRAX® Clinical Regarding International Differences. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®Journal of Clinical Densitometry.  14:240-262. 2011
    2011 Which fractures are most attributable to osteoporosis?Journal of Clinical Epidemiology.  64:46-53. 2011
    2010 Predicting hip and major osteoporotic fractures using administrative dataArchives of Internal Medicine.  170:1940-1942. 2010
    2010 Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral ResearchJournal of Bone and Mineral Research.  25:2267-2294. 2010
    2010 Explaining the cardiovascular risk associated with rheumatoid arthritis: Traditional risk factors versus markers of rheumatoid arthritis severityAnnals of the Rheumatic Diseases.  69:1920-1925. 2010
    2010 Consistency of knee pain: Correlates and association with functionOsteoarthritis and Cartilage.  18:1250-1255. 2010
    2010 Converting modified Health Assessment Questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patientsArthritis Care and Research.  62:1481-1488. 2010
    2010 Osteoporosis care in the United States after declines in reimbursements for DXAJournal of Clinical Densitometry.  13:352-360. 2010
    2010 Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosisOsteoporosis International.  21:1573-1584. 2010
    2010 Health services utilization after fractures: Evidence from Medicare 2010
    2010 Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  69:1612-1617. 2010
    2010 The delivery of evidence-based preventive care for older Americans with arthritis 2010
    2010 Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US national osteoporosis foundation guidelinesJournal of Bone and Mineral Research.  25:1506-1511. 2010
    2010 Identifying types of nursing facility stays using medicare claims data: An algorithm and validation 2010
    2010 Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologicsMedical Care.  48. 2010
    2010 Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: A review of the literature and a case report 2010
    2010 Pre-radiographic MRI findings are associated with onset of knee symptoms: the most studyOsteoarthritis and Cartilage.  18:323-328. 2010
    2010 Vitamin D status and its associations with disease activity and severity in african americans with recent-onset rheumatoid arthritisJournal of Rheumatology.  37:275-281. 2010
    2010 Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activityArthritis Care and Research.  62:101-107. 2010
    2010 A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries1Seminars in Arthritis and Rheumatism.  40:2-14.e1. 2010
    2010 American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.Arthritis Care and Research.  62:1515-1526. 2010
    2010 Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomideAnnals of the Rheumatic Diseases.  69:43-47. 2010
    2010 High systemic bone mineral density increases the risk of incident knee OA and joint space narrowing, but not radiographic progression of existing knee OA: The MOST studyAnnals of the Rheumatic Diseases.  69:163-168. 2010
    2010 Is withholding osteoporosis medication after fracture sometimes rational? A Comparison of the risk for second fracture versus death 2010
    2009 Health care expenditures associated with skeletal fractures among medicare beneficiaries, 1999-2005Journal of Bone and Mineral Research.  24:2050-2055. 2009
    2009 "pathologic" fractures: Should these be included in epidemiologic studies of osteoporotic fractures?Osteoporosis International.  20:1969-1972. 2009
    2009 Do physicians within the same practice setting manage osteoporosis patients similarly? Implications for implementation researchOsteoporosis International.  20:1921-1927. 2009
    2009 Skeletal health among African Americans with recent-onset rheumatoid arthritisArthritis Care and Research.  61:1379-1386. 2009
    2009 Quality health care gaps in osteoporosis: How can patients, providers, and the health system do a better job?Current Osteoporosis Reports.  7:27-34. 2009
    2009 Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory MechanismsSeminars in Arthritis and Rheumatism.  39:132-143. 2009
    2009 Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare dataOsteoporosis International.  20:1507-1515. 2009
    2009 The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United StatesOsteoporosis International.  20:1553-1561. 2009
    2009 Adherence to osteoporosis treatments: Room for improvementCurrent Opinion in Rheumatology.  21:356-362. 2009
    2009 RisedronatE and ALendronate intervention over three years (REALITY): Minimal differences in fracture risk reductionOsteoporosis International.  20:973-978. 2009
    2009 Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: A population-based cohort studyOsteoporosis International.  20:819-826. 2009
    2009 Management of osteoporosis among home health and long-term care patients with a prior fractureSouthern Medical Journal.  102:397-404. 2009
    2009 Improving the prediction of medication compliance: The example of bisphosphonates for osteoporosisMedical Care.  47:334-341. 2009
    2009 Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patientsJournal of Clinical Epidemiology.  62. 2009
    2009 Bridging the osteoporosis quality chasmJournal of Bone and Mineral Research.  24:3-7. 2009
    2009 Identification and validation of vertebral compression fractures using administrative claims dataMedical Care.  47:69-72. 2009
    2009 Population-based fracture risk assessment and osteoporosis treatment disparities by race and genderJournal of General Internal Medicine.  24:956-962. 2009
    2009 Validity of physician-reported hospitalized infections in a US arthritis registry.Rheumatology.  48:1269-1272. 2009
    2008 Tumor necrosis factor inhibitors and infection complicationsCurrent Rheumatology Reports.  10:383-389. 2008
    2008 Risk of hip fracture after bisphosphonate discontinuation: Implications for a drug holidayOsteoporosis International.  19:1613-1620. 2008
    2008 Muscle Mass Is More Strongly Related to Hip Bone Mineral Density Than Is Quadriceps Strength or Lower Activity Level in Adults Over Age 50 YearJournal of Clinical Densitometry.  11:503-510. 2008
    2008 Regional Variation in the Denial of Reimbursement for Bone Mineral Density Testing Among US Medicare BeneficiariesJournal of Clinical Densitometry.  11:568-574. 2008
    2008 Adaptation of bayesian data mining algorithms to longitudinal claims data: Coxib safety as an exampleMedical Care.  46:969-975. 2008
    2008 Benefit of adherence with bisphosphonates depends on age and fracture type: Results from an analysis of 101,038 new bisphosphonate usersJournal of Bone and Mineral Research.  23:1435-1441. 2008
    2008 Mortality and osteoporotic fractures: Is the link causal, and is it modifiable?Clinical and Experimental Rheumatology.  26. 2008
    2008 Mortality and osteoporotic fractures: is the link causal, and is it modifiable?Clinical and Experimental Rheumatology.  26:S125-S137. 2008
    2008 Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005Journal of Bone and Mineral Research.  23:1061-1067. 2008
    2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisArthritis Care and Research.  59:762-784. 2008
    2008 Leg-length inequality is not associated with greater trochanteric pain syndrome 2008
    2008 Association of infections and tuberculosis with antitumor necrosis factor alpha therapyCurrent Opinion in Rheumatology.  20:320-326. 2008
    2008 Biologics and heart failure in rheumatoid arthritis: Are we any wiser?Current Opinion in Rheumatology.  20:327-333. 2008
    2008 Improving quality of care in osteoporosis: Opportunities and challengesCurrent Rheumatology Reports.  10:123-130. 2008
    2008 The epidemiology of glucocorticoid-associated adverse eventsCurrent Opinion in Rheumatology.  20:131-137. 2008
    2008 Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal antiinflammatory drugsArthritis Care and Research.  59:227-233. 2008
    2007 Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behaviorArthritis Care and Research.  57:1539-1545. 2007
    2007 Challenges in defining and improving osteoporosis quality of careClinical and Experimental Rheumatology.  25. 2007
    2007 Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonistsArthritis and Rheumatism.  56:4226-4227. 2007
    2007 Challenges in defining and improving osteoporosis quality of care.Clinical and Experimental Rheumatology.  25:142-146. 2007
    2007 Greater Trochanteric Pain Syndrome: Epidemiology and Associated FactorsArchives of Physical Medicine and Rehabilitation.  88:988-992. 2007
    2007 Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fractureOsteoporosis International.  18:553-559. 2007
    2007 Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonistsArthritis and Rheumatism.  56:1125-1133. 2007
    2007 Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: A prospective randomized trialArchives of Internal Medicine.  167:591-596. 2007
    2007 Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugsArthritis Care and Research.  57:343-346. 2007
    2007 Prevention and treatment of glucocorticoid-induced osteoporosisCurrent Osteoporosis Reports.  5:14-21. 2007
    2007 Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-α antagonistsRheumatology.  46:1688-1693. 2007
    2006 Osteoporosis in the home health care setting: A window of opportunity?Arthritis Care and Research.  55:971-975. 2006
    2006 Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid usersPharmacoepidemiology and Drug Safety.  15:710-718. 2006
    2006 Channeling and adherence with alendronate and risedronate among chronic glucocorticoid usersOsteoporosis International.  17:1268-1274. 2006
    2006 Trends in prevention of glucocorticoid-induced osteoporosisJournal of Rheumatology.  33:1651-1657. 2006
    2006 Population-based assessment of adverse events associated with long-term glucocorticoid useArthritis Care and Research.  55:420-426. 2006
    2006 Medication errors with the use of allopurinol and colchicine: A retrospective study of a national, anonymous internet-accessible error reporting systemJournal of Rheumatology.  33:562-566. 2006
    2006 Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventionsPharmacoepidemiology and Drug Safety.  15:11-18. 2006
    2005 Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patientsArthritis and Rheumatism.  52:2485-2494. 2005
    2005 Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: The impact of ethnic-specific normative dataJournal of the National Medical Association.  97:1155-1160. 2005
    2004 Swallowing difficulties from "DISH-phagia"Journal of Rheumatology.  31:2526-2527. 2004
    2004 Evaluating and improving the quality of care in rheumatic disease 2004
    2004 Vitamin D Intake Is Inversely Associated With Rheumatoid Arthritis: Results From the Iowa Women's Health StudyArthritis and Rheumatism.  50:72-77. 2004
    2003 Nonsteroidal Antiinflammatory Drug Toxicity Monitoring and Safety PracticesJournal of Rheumatology.  30:2680-2688. 2003
    2003 The Use of Glucocorticoids in Arthritis – 20 Clinical PearlsThe Journal of Musculoskeletal Medicine.  20:425-433. 2003
    1985 ReplyAmerican Journal of Ophthalmology.  99:220. 1985

    Chapter

    Year Title Altmetric
    2019 Study of biologics and biosimilars.  561-580. 2019
    2009 Bisphosphonate Therapy for Osteoporosis 2009
    2008 Glucocorticoid-Induced Osteoporosis.  1135-1166. 2008
    2005 Prevention and Treatment 2005
    2004 Therapeutic Dictionary of Rheumatology and Immunology 2004
    2001 Glucocorticoid-induced osteoporosis.  140-145. 2001
    2000 New Biologics: Cytokines 2000

    Research Overview

  • Rheumatoid Arthritis
    Psoriatic Arthritis
    Ankylosing Spondylitis
    Osteoporosis
  • Principal Investigator On

  • A Pilot Study of the Safety and Effectiveness of the Live Zoster Vaccine in Anti-TNF Users  awarded by RHEUMATOLOGY RESEARCH FOUNDATION
  • ACE - Switching Anti-TNF-a Agents in Patients with RA with an Inadequate Response to TNF-a Inhibition - ACE  awarded by Duke University
  • ACE Protocol #ARA06  awarded by Duke University
  • ACR RISE Registry-NQF  awarded by American College of Rheumatology
  • Arthritis Foundation Investigator Award: Osteoporosis and Associated Stroke and MI in a Multi-Ethnic Cohort  awarded by Arthritis Foundation
  • Arthritis Patient Partnership With Comparative Effectiveness Researchers (AR-Power PPRN)  awarded by GLOBAL HEALTHY LIVING FOUNDATION
  • Arthritis Patient Partnership with Comparative Effectiveness Researchers (Arthritis Patient PoWER)  awarded by GLOBAL HEALTHY LIVING FOUNDATION
  • Building and InnovatinG: Digital heALTH Technology and Analytics (BIGDATA)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Building and InnovatinG: Digital heAlth Technology and Analytics (BIGDATA) - Administrative Core  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Centers of Research Translation (CoRT) - Project 4  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis  awarded by Oregon Health & Science University
  • Coronary Heart Disease in Rheumatoid Arthritis  awarded by Arthritis Foundation
  • Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-Management  awarded by University of North Carolina at Chapel Hill
  • Ethnic Differences in the Risk of Fracture and Vascular Disease  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Exploring Rheumatoid Arthritis Patients’ Disease Activity Using ArthritisPower Registry Patient Reported Outcome Measures and Biometric Sensor Data.  awarded by GLOBAL HEALTHY LIVING FOUNDATION
  • Harnessing PCORnet to Study Comparative Effectiveness and Safety of Biologic Therapies  awarded by PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE
  • Kaiser Permanente Autoimmune Disease Registry  awarded by Kaiser Permanente
  • Long Term Risks and Extra-Skeletal Benefits of Biologics  awarded by Duke (Doris) Charitable Foundation
  • Longitudinal Comparative Effectiveness & Safety of Biologics in Autoimmunity  awarded by Agency for Healthcare Research and Quality/DHHS
  • Making PROMISE Meaningful to Patients and Providers in Clinical Practice  awarded by Johns Hopkins University
  • Patient Valued Comparative Effectiveness of Corticosteroids Versus Anti-TNF Alpha Therapy for Inflammatory Bowel Disease  awarded by University of Pennsylvania
  • Privacy-Preserving Analytic and Data-Sharing Methods for Clinical and Patient-Powered Research Data Research Networks  awarded by HARVARD PILGRIM HEALTH CARE
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by ABBOTT LABORATORIES
  • Private Grant  awarded by Centocor
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by KNOLL PHARMACEUTICAL COMPANY
  • Private Grant  awarded by CONSORTIUM OF RHEUMATOLOGY RESEARCHERS OF NORTH AMERICA, INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by WYETH PHARMACEUTICALS, INC.
  • Private Grant  awarded by CONSORTIUM OF RHEUMATOLOGY RESEARCHERS OF NORTH AMERICA, INC.
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC.
  • Private Grant  awarded by UCB PHARMA, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by UCB PHARMA, INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by ANOLINX, LLC
  • Private Grant  awarded by UCB PHARMA, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by UCB, INC.
  • Private Grant  awarded by UCB, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by ACTURIAL RESEARCH CORPORATION
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC.
  • Private Grant  awarded by RADIUS HEALTH
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by SETPOINT MEDICAL CORPORATION
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by BENDCARE
  • Private Grant  awarded by BENDCARE
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by ABBVIE INC
  • Safety and Effectiveness of Herpes Zoster Vaccination in Rheumatoid Arthritis Patients  awarded by American College of Rheumatology
  • Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • The TAKEOFF Trial: Clinical Trial Planning Grant  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Treatments Against RA and Effect of FDG PET-CT: The TARGET Trial  awarded by Brigham and Women's Hospital
  • UAB Multidisciplinary Clinical Research Center - Project 2: Facilitating Treat-to-Target Using Novel Health Technology with Decision Support  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Investigator On

  • A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients with Rheumatoid Arthritis with Active Disease Despite Methotrexate  awarded by PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE
  • ACE Protocol ARA08: Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA)  awarded by University of California, San Francisco
  • ARA08 - Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA)  awarded by Emory University
  • ARA08 - Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA)  awarded by Emory University
  • Biomarker-Defined Precision Medicine in Seropositive Rheumatoid Arthritis  awarded by American College of Rheumatology
  • Brain Thermometry: A Non-Invasive Method for Detecting Neuroinflammation in RA  awarded by RHEUMATOLOGY RESEARCH FOUNDATION
  • Burden of Osteoporosis and Low Bone Density in the United States  awarded by National Osteoporosis Foundation
  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Deep South Musculoskeletal Certs (DSMC)  awarded by Agency for Healthcare Research and Quality/DHHS
  • Diversifying, Expanding and Tracking Patient Engagement in Arthritis Research  awarded by GLOBAL HEALTHY LIVING FOUNDATION
  • Does Aggressive Treatment in Early RA Reduce Biomarkers of Cardiovascular Risk?  awarded by University of California, Los Angeles
  • Effectiveness of DiscontinuinG BisphosphonatEs Study (EDGE)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Effectiveness of Pegloticase Associated with the Use of Concomitant Immunomodulatory Therapy  awarded by American College of Rheumatology
  • Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis  awarded by RHEUMATOLOGY RESEARCH FOUNDATION
  • Evaluating Quality Measures In Childhood-Onset System Lupus Erythematosus  awarded by RHEUMATOLOGY RESEARCH FOUNDATION
  • Evaluation of Geographic Variation in Rheumatoid Arthritis Disease Burden in Routine Care  awarded by American College of Rheumatology
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Administrative Core  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Modifications to Implement Lupus Decision-Aid Successfully in COVID-19 Era  awarded by PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE
  • Multimorbidity in Rheumatoid Arthritis  awarded by American College of Rheumatology
  • NIAMS Multidiscipllinary Clinical Research Center  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • NIAMS Multidiscipllinary Clinical Research Center - Project 4  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Promo/Dissemination Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Tech Developments Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS
  • Outliers - Extreme Long-term Survivors with Metastatic Breast Cancer  awarded by University of Wisconsin-Madison
  • Patient Characteristics for RA Patients Who Were Treated With Sarilumab (Kevzara)  awarded by American College of Rheumatology
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC.
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC.
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by Janssen
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Rehabilitation Research Resource to Enhance Clinical Trials (REACT)  awarded by National Institute of Child Health and Human Development/NIH/DHHS
  • Strengthening Translational Research in Diverse Enrollment (STRIDE)  awarded by UNIVERSITY OF MASSACHUSETTS (WORCESTER)
  • The Relationship of Disease Activity to Medication use in the RISE Registry  awarded by American College of Rheumatology
  • UAB Deep South Arthritis and Musculoskeletal CERTs  awarded by Agency for Healthcare Research and Quality/DHHS
  • UAB Multidisciplinary Clinical Research Center (P60)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Education And Training

  • Oregon Health Science University Hospital & Clinic, Internship
  • Oregon Health Science University Hospital & Clinic, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Oregon Health Sciences University 1999
  • Master of Public Health, Oregon Health Sciences University 1999
  • Full Name

  • Jeffrey Curtis